Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cancer
Roche pays $2.4 billion for rest of Foundation Medicine
by Lisa Jarvis
June 23, 2018
| A version of this story appeared in
Volume 96, Issue 26
Roche will pay $2.4 billion to acquire the portion of genomic profiling firm Foundation Medicine that it doesn’t already own. Foundation develops tests that pinpoint the genetic defect driving a person’s cancer, allowing tailored treatments. Roche bought a majority stake in the firm in early 2015 for $1.3 billion. The deals dovetail with Roche’s strategy to focus on personalized health care. Foundation will operate as a separate entity.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter